Know Cancer

forgot password

Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)

18 Years
90 Years
Open (Enrolling)
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer

Thank you

Trial Information

Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)

This protocol is designed to collect a small amount of blood for extraction of DNA (genetic
material) for the study of the genetic basis of lung disease. The study population will
include individuals with known lung diseases and controls without lung disease. Individuals
in the study population will be individuals at the Hamad Medical Corporation, Qatar (HMC),
as well as other individuals recruited for this study. In this protocol, researchers will
survey medical records of patients with chronic lung disease, in order to study the clinical
characteristics of these individuals, and the researchers will collect blood to evaluate the
genetic characteristics of individuals with chronic lung diseases including asthma, and COPD
(chronic obstructive pulmonary disease), pulmonary fibrosis, and lung cancer. The
researchers will also collect blood samples of individuals without lung disease to serve as

This protocol, to be carried out at Weill Cornell Medical College - Qatar and Hamad Medical
Corporation, Qatar, parallels a similar approved protocol IRB #0508008095, entitled,
"Collection of Blood for Gene Expression/Genomic Studies in Individuals with Chronic Lung
Diseases", ongoing at Weill Cornell Medical College - New York.

Lung Disease group. Individuals with lung disease who fit the following criteria will be

Inclusion criteria

- Must provide informed consent

- Males and females, age 18 years and older

- Evidence of lung disease proven by at least one of the following: (1) symptoms
consistent with pulmonary disease; (2) chest X-rays and/or chest CT consistent with
lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung
biopsy consistent with lung disease; (5) family history of lung disease; and (6)
diseases of organs with known association with lung disease; and (7) individuals
suspected of history of lung diseased based on history and/or physical examination

Exclusion criteria

- Individual refuses consent.

Normal control group. For the purpose of this protocol, "normal" will include individuals
without history of chronic lung disease, including asthma, and without recurrent or recent
(within 3 months) acute pulmonary disease, and will be determined by the following

Inclusion Criteria:

- Must provide informed consent.

- Males or females ages 18 years and older.

- Non-smokers, ex-smokers and smokers.

Exclusion Criteria:

- Individual refuses consent.

- Individuals with history of chronic lung disease, including asthma or with
recurrent or recent (within three months) acute pulmonary disease will not be
accepted into the study.

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Ronald G Crystal, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Weill Cornell Medical College, NY and Qatar


United States: Institutional Review Board

Study ID:




Start Date:

May 2006

Completion Date:

May 2012

Related Keywords:

  • Asthma
  • COPD
  • Interstitial Lung Disease
  • Cystic Fibrosis
  • Lung Cancer
  • Asthma
  • COPD
  • Interstitial Lung Disease
  • Cystic Fibrosis
  • Lung Cancer
  • smokers
  • non-smokers
  • Asthma
  • Cystic Fibrosis
  • Fibrosis
  • Lung Diseases
  • Pulmonary Disease, Chronic Obstructive
  • Lung Neoplasms
  • Pulmonary Fibrosis
  • Lung Diseases, Interstitial